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Abstract
Introduction: Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide. Multiple genetic and epigenetic changes are involved
in the molecular pathogenesis of HCC. Heat shock proteins have essential roles
in protecting cells from the potentially lethal effects of stress. Among them,
HSP70 are often overexpressed in cells of various cancers and have been
suggested to contribute to tumourigenesis. p53 mutations in codon 249 have
also been identified in HCC. 
Material and methods: Fifty patients with liver disease were enrolled in this
study compared to 10 healthy volunteers. The studied patients were divided
into 2 groups: group I includes those suffering from HCC, group II includes those
suffering from post-hepatitis B and C liver cirrhosis. The presence of p53 gene
mutation was detected by DNA extraction from whole blood of patients and
controls followed by polymerase chain reaction then restriction fragment length
polymorphism (RFLP) analysis of codon 249 of exon 7. We also studied the
genotypes of the HSP70 gene by PCR followed by RFLP analysis.
Results: Our results revealed no statistical difference between group I, group II,
and the control group as regards exon 7 mutation of the p53 gene. Also the
frequency of polymorphic genotypes of HSP70 showed no significant difference
between the 3 studied groups.
Conclusions: The present study supports the view that the incidence of point
mutation of p53 codon 249 mutations in exon 7 of the p53 gene may not play
a role in carcinogenesis of HCC in Egyptian patients. Also, genetic polymorphism
in HSP70 was not associated with high risk of future development of HCC. 
Key words: hepatocellular carcinoma, p53, HSP70, hepatitis C virus, hepatitis B
virus.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide and is estimated to cause over one million deaths
every year. Risk factors include chronic hepatitis B and C virus infections
and exposure to aflatoxin B1. Chronic hepatitis B virus (HBV) and hepatitis C
virus HCV infections are the major risk factors for the development of
hepatocellular carcinoma (HCC) through a multistep pathway that involves
viral and non-viral-dependent pathophysiological steps [1].
Besides being useful in identifying people at risk for a genetically based
disease, knowledge of the polymorphisms that cause disease can provide
valuable insight into how the disease develops [2].
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Mutation or deletion of the p53 gene, which
plays an important role in cell growth, division and
apoptosis by acting as a transcription factor or by
forming complexes with other proteins, is
frequently detected in HCC. In addition, loss of the
functional p53 gene is associated with lower cellular
differentiation and poor prognosis [3].
Abnormalities of p53 are also considered
a predisposing factor for hepatocarcinogenesis.
Hence, restoration of a wild-type p53 gene is an
attractive approach to the treatment of HCC [4].
p53 mutations have been identified in several
human cancers. A selective G to T transversion
mutation at codon 249 (AGG → AGT, arginine to
serine) of the p53 gene has been identified as
a “hotspot” mutation for hepatocellular carcinoma
(HCC) in the Qidong area [5].
Heat shock proteins (HSPs) are overexpressed
in a wide range of human cancers, and are
implicated in tumour cell proliferation, differ  -
entiation, invasion, metastasis, death, and
recognition by the immune system [6].
The incidence of hepatocellular carcinoma (HCC)
is increasing worldwide and accounts for as many
as 1.2 million deaths annually, especially in Asia and
Southern Africa. Most HCCs are associated with
chronic liver diseases resulting from hepatitis B or
C viral infection, and the processes of chronic
inflammation and fibrosis act as a stressful
condition. Heat shock proteins induced in response
to this stressful condition may contribute to
hepatocarcinogenesis. Until now there have been
a few comprehensive studies of the expression of
HSP70 in HCC; however, its prognostic relevance
remains controversial. In addition, there have been
few studies on HSP70 expression in association with
tumour cell proliferation or apoptosis in HCCs [7]. 
The objective of this work is: to clarify the relation
between the selective mutation resulting in a serine
substitution at codon 249 in exon 7 of the p53 gene
among patients with hepatocellular carcinomas and
patients with cirrhosis, occurring in populations with
viral hepatitis B or C infections in Egypt; and also to
investigate whether polymorphism in the heat shock
protein 70 (HSP70) gene has any bearing on
individual susceptibility to the development of HCC.
Material and methods
The current study was conducted on 50 patients
with liver disease. They were admitted to the
Tropical Department of Kasr El Aini Hospital during
the year 2007. The study was approved by the
ethical committee. The studied patients were
divided into 2 groups: group I (HCC) – included 
20 subjects suffering from HCC, 17 males (85%) and
3 females (15%), aged between 42 years and 
70 years with a mean of 61.9 ±7.07; group II (LC) –
included 30 subjects suffering from post-hepati  -
tis B and/or C liver cirrhosis, 14 males (46.7%) and 
16 females (53.3%), aged between 36 years and 
77 years with a mean of 52.2 ±9.4. Control group:
comprised 10 healthy volunteers not suffering from
any liver disease. They were 6 males (60%) and 
4 females (40%) aged from 50 years to 65 years
(mean of 59 ±4.76 years).
Diagnosis included clinical, laboratory and
radiological findings. The controls were recruited
from outpatient clinics among individuals with no
history or clinical findings suggestive of liver
disease, and having the same distributions of age,
gender and recruitment site as the HCC and LC
(liver cirrhosis) patients.
Determination of p53 mutation
DNA extraction: 200 µl of whole EDTA blood was
used for genomic DNA extraction using QIAamp
DNA Mini Kit (Catalogue No. 51104), QIAGEN.
DNA amplification and PCR analysis of exon 7
The PCR primers used were as follows:
Primer 1 (up) (5’-CTT GCC ACA GGT CTC CCC AA-3’), 
Primer 2 (down) (5’-AGG GGT CAG CGG CAA GCA
GA-3’).
All reactions were performed in a total volume
of 50 µl containing: 25 µl Taq Master Mix (QIAGEN). 
The thermocycling procedure was done in a PE
9700 (Perkin-Elmer, Foster City, CA) with an initial
denaturation step of 5 min at 94°C followed by 
40 cycles of 94°C for 30 s, annealing at 60°C for 
30 s and 72°C for 30 s, and finally extension at 72°C
for 10 min. The 254-bp long amplified PCR products
were electrophoresed on 4% agarose gel, stained
with ethidium bromide, and visualized by a UV
transilluminator.
Mutation detection by restriction analysis
The 254 bp extracted DNA fragment, derived
from exon 7 of the p53 gene, was submitted to
restriction enzyme Hae III (BsuRI) from Fermentas
Life Science.
A mutation at codon 249-250 will result in an
uncleaved 158-bp fragment, and this feature will be
distinguished from that of normal samples
generating 92 bp, 66 bp and several small
fragments from the 254 bp amplified DNA PCR
product. Electrophoresis on 4% agarose gel stained
with ethidium bromide will distinguish positive
cases (with 249 mutation) from negative ones and
controls (wild-type). The samples were then
visualized on a UV transilluminator (Figures 1, 2).
Determination of HSP70 gene polymorphism
The same steps as previously done for p53, but
using the following different primers for HSP70-1
and HSP70-2:
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HSP70-1
The PCR primers used were as follows:
(Forward) 5’-TCCGGCGTCCGGAAGGACC-3’,
(Reverse) 5’ -TGCGGCCAATCAGGCGCTT-3 ’.
Mutation detection by restriction analysis using:
the biallelic polymorphism at position 190 in the
HSP70-1 gene was detected by BsrBI restriction
enzyme digestion of the fragment of 325 bp DNA
which was previously amplified by the above-
mentioned primers. The restriction enzyme BseNI
(BsrBI) used was from Fermentas Life Science. 
The presence of the 171 bp, 84 bp and 70 bp
fragments represents the HSP70-1*b1 allele,
whereas the b2 allele showed only 2 fragments of
241 bp and 84 bp. Electrophoresis on 4% gel and
staining with ethidium bromide distinguishes the
2 genotypes from each other (Figure 3).
HSP70-2
The PCR primers used were as follows: an
HSP70-2 restriction fragment length polymorphism
at position 1267 was characterized by a PCR
procedure. This analysis was performed considering
the polymorphic PstI site at position 1267 of these
alleles. We used the following primers spanning
the polymorphic PstI site (nucleotide 1267)
according to the following described sequence,
sense (nucleotide 1083-1102 within the 
coding region) 5’-CATCGACTTCTACACGTCCA-3’ and 
anti  sense (nucleotide 2180-2199 within the 3’ 
untra  nslated end to avoid HSP70-1 homology) 
5’-CAAAGTCCTTGAGTCCCAAC-3’.
Mutation detection by restriction analysis
The same steps as previously described but using
the restriction enzyme PstI from Fermentas Life
Science. 
Detection of the PCR RFLP products using 4% gel
electrophoresis stained with ethidium bromide and
ultraviolet light transillumination. The DNA-lacking
polymorphic PstI site within the HSP70-2 gene
generated a product of 1117 bp after restriction 
(A allele), whereas the PstI site produced 2 frag  -
ments of 936 bp and 181 bp (B allele) (Figure 4).
Figure 1. Gel electrophoresis (4%) showing exon 7
mutation of p53 gene by PCR-RFLP technique using
restriction enzyme HaeIII revealed the following:
lanes 1, 2, 3, 4 and 5 – negative controls; lanes 6 and
9 – positive cases of HCC samples revealing
uncleaved 158 bp, 92 bp, and 66 bp fragments
denote heterozygous mutation; lanes 7, 8, 10 → 19
are negative cases of group I and II revealing 92 bp
and 66 bp fragments denoting wild type p53
Figure 2. Homozygous mutation of exon 7 of p53
gene stained with ethidium bromide on 4% gel.
Mutation at codon 249 was identified by restriction
enzyme HaeIII. Lane 10 is the only HCC case revealing
an uncleaved, 158 bp fragment
Figure 3. Characterization of BseNI polymorphism of
the HSP70-1 gene. Ethidium bromide stained gel of
the PCR products digested with BseNI. Amplification
of genomic DNA from different individuals containing
the 2 possible genotypes is shown. Lane 10 is the DNA
marker (50 bp), lanes 1, 2, 3 represent b2/b2 genotype,
2 bands of 84 and 241 bp, lanes 4, 5, 6, 7, 8 and 
9 represent b1/b1 genotype, 3 bands of 70, 84, 171 bp
Figure 4. Ethidium bromide stained gel of the PCR
products digested with PstI of the HSP70-2. Individuals
containing 3 different possible genotypes are shown:
lane 1 is the DNA marker (50 bp), lanes 6, 7, 8, 9 and
10 represent AB genotype, 3 bands of 1117, 936 and
181 bp, lanes 5, 11 and 12 represent AA genotype, one
band of 1117 bp, lane 13 represents BB genotype, 
2 bands of 936 and 181 bp
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Statistical analysis
Data were collected, revised, verified then edited
on a PC. Data were then analysed statistically using
SPSS statistical package version 13. Comparisons
between groups were made using t-test and χ2 test.
A value of p < 0.05 was considered statistically
significant.
Results
Mean and SD of liver function tests in groups I
(HCC) and II (liver cirrhosis) is showed in Table I,
comparison between groups I (HCC) and II (liver
cirrhosis) as regards positive hepatitis markers in
Figure 5, and α-fetoprotein (AFP) (ng/dl) in the 
3 studied groups in Table II.
Codon 249 mutation in exon 7 of p53 gene 
Regarding mutation of codon 249 in exon 7 of
the p53 gene using PCR-RFLP technique, our work
gave the following results: among the controls, no
point mutation at codon 249 of exon 7 was
detected. Group II (liver cirrhosis) also revealed no
mutation at that point. In group I (HCC), 3 out of 
20 patients (15%) had this G to T transversion at
the third base of codon 249 of the p53 gene,
whereas 17 patients (85%) were wild type (Figure 1).
One of the 3 mutated patients was homozygous
for the mutation (both alleles of the p53 gene were
mutated) while the other 2 patients were
heterozygous for the same mutation (Figure 1 –
lanes 6 and 9 positive cases; heterozygous
mutation; Figure 2 – lane 10 positive case;
homozygous mutation).
Patients showing the mutations were males only,
but we cannot consider it as a difference, because
of the small number of females included in the
study group (3 out of 20).
HCV-Ab HBsAg HBc-Ab
Figure 5. Comparison between groups I (HCC) and II
(liver cirrhosis) as regards positive hepatitis markers
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Group I HCC Group II (Liver cirrhosis)
HCC (n = 20) Cirrhosis (n = 30) Value of p
ALT [U/l] 82.4 ±46.37 34.73 ±22.56 < 0.001**
AST [U/l] 113.15 ±77.12 51.9 ±27.6 < 0.001**
T-Bili [mg/dl] 1.73 ±1.96 2.45 ±3.44 > 0.05
D-Bili [mg/dl] 0.97 ±1.71 1.25 ±2.33 > 0.05
T-protein [g/dl] 7.03 ±0.83 7.17 ±0.99 > 0.05
Albumin [g/dl] 3.09 ±0.59 3.03 ±0.70 > 0.05
GGT [U/l] 139.8 ±123 44.96 ±31.5 < 0.001**
AFP [ng/dl] 387.98 ±539.45 6.32 ±3.81 < 0.001**
PT [%] 80.25 ±9.4 76.89 ±13.2 > 0.05
p > 0.05 – non-significant, *p < 0.05 – significant, **p < 0.001 – highly significant
Table I. Mean and SD of liver function tests in groups I (HCC) and II (liver cirrhosis)
AFP [ng/dl] Value of p
Range Mean ± SD
HCC group (n = 20) 15.5-2477 378.9 ±539.4 < 0.001**
Cirrhosis group (n = 30) 0.8-15.3 6.32 ±3.81
HCC group (n = 20) 15.5-2477 378.9 ±539.4 < 0.05*
Controls (n = 10) 1.3-5.1 1.3-5.1
Cirrhosis group (n = 30) 0.8-15.3 6.32 ±3.81 > 0.05
Controls (n = 10) 1.3-5.1 1.3-5.1
p > 0.05 – non-significant, *p < 0.05 – significant, **p < 0.001 – highly significant
Table II. α-Fetoprotein (AFP) in the 3 studied groups
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Patients with 249ser mutation showed no
statistically significant difference in mean age from
those without the mutation (p = 0.22) (Figure 6).
Polymorphism of HSP70-1
The polymorphism of HSP70-1 was examined
and revealed the following genotype frequency in
Egyptian patients in group I (HCC) and group II (liver
cirrhosis) and in healthy controls (Figure 7).
The frequency of polymorphic genotypes showed
no significant difference between the 3 studied
groups (p > 0.05), although the HSP70-1 b2b2
genotype is dominant in the 3 groups.
Polymorphism of HSP70-2
The genotype frequencies of individuals
homozygous for allele A (AA), heterozygous for
alleles A and B (AB) and homozygous for allele B
(BB) among the 3 studied groups are shown in
Table III. 
The frequency of polymorphic genotypes showed
no significant difference between the 3 studied
groups (p > 0.05):
HSP70-2 A/B and B/B genotypes between group
I and control OR 3 (95% CI = 0.606-14.86),
HSP70-2 A/B and B/B genotypes between group II
and control OR 3.5 (95% CI = 0.753-16.263).
Discussion
The current study was conducted on 50 subjects
with liver disease compared to 10 age- and sex-
matched healthy volunteers representing the
control group. The study group was subdivided into
group I that included 20 subjects suffering from
HCC and group II that included 30 subjects suffering
from post-hepatitis B and/or C liver cirrhosis.
Our study revealed that in group I (HCC), 14/20
patients (70%) were seropositive for HCV-Ab, and
in group II (liver cirrhosis), 24/30 (80%) were
seropositive for HCV-Ab.
Hassan et al. [9] estimated the risk of HCC in
relation to HCV and HBV in Egypt. Thirty-three
patients with HCC and 35 healthy controls who had
a similar socioeconomic status were prospectively
enrolled. They estimated the attributable fraction
of HCC to HCV to be 64% in the studied population
and 48% in the general Egyptian population. They
concluded that both HCV and hepatitis B virus
infection increase the risk of HCC in Egyptian
patients. However, because of the very high
prevalence of HCV in the general Egyptian
population, it accounts for most HCC cases in Egypt.
Chronic HBV infection is one of the most
important risk factors for HCC in humans. It is
estimated that 80% of HCC worldwide is
aetiologically associated with HBV. In the United
Group 1  Group 2 Control 
HCC Liver cirrhosis group
Figure 6. Comparison between the 3 groups as
regards exon 7 mutation
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Figure 7. Comparison between 3 groups as regards
HSP70-1 genotypes
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b1b1 genotype b2b2 genotype
HSP70-2 HCC (n = 20) No. (%) Liver cirrhosis (n =30) No. (%) Control (n = 10) No. (%)
Genotype
A/A   0 3 (10%) 0
A/B 5 (25%) 6 (20%) 5 (50%)
B/B 15 (75%) 21 (70%) 5 (50%)
Alleles
A 5 (12.5%) 12 (20%) 5 (25%)
B  35 (87.5%) 48 (80%) 15 (75%)
Table III. Comparison between 3 groups as regards HSP70-2 genotypes
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States, although the infection rate is low, HBV is
estimated to account for one fourth of HCC cases
among non-Asians [10]. In our current study HBsAg
was present in 30% of the patients in group I (HCC)
and in 20% of group II with liver cell cirrhosis 
(p > 0.05).
Mutation or deletion of the p53 gene, which
plays an important role in cell growth, division and
apoptosis by acting as a transcription factor or by
forming complexes with other proteins, is
frequently detected in HCC. Codon 249 of p53 is
a hotspot for AFB1 modification and AFB1-induced
mutation, specifically AGGC → AGTC. This mutation
has been found in up to 50% of HCC samples in
areas of the world where aflatoxin exposure is high.
To date, over 2000 HCC samples from all over the
world have been examined for this mutation [3].
Kirk et al. [11] reported that, in regions where
exposure to aflatoxin is high, namely in Qidong and
Tongan (China), India, Southern Africa, Gambia,
Mozambique and Senegal, 116 out of 262 (44%) 
of the total HCC cases examined showed
a predominance of GC  TA mutations at the third
position of codon 249 of the p53 gene. In contrast,
in regions of low exposure to aflatoxin, namely
Australia, Europe, Japan and the USA, only 17 out
of 1273 (1%) of the HCC samples examined had
mutations at this site [12]. 
Sohn et al. [13] demonstrated that in regions
where exposure to aflatoxin is moderate – namely
Beijing, Shanghai, Hong Kong, Singapore, South
Korea, Taiwan, Southern Asia, South Africa and
Egypt – 40 out of 568 (7%) HCC cases examined
had mutations at the third position of codon 249 of
the p53 gene. This p53 mutation appears to be
unique to AFB1-induced liver tumours, as tumours
presumably induced by other factors fail to
consistently show this genetic change.
In our study, examination of the DNA extracted
from whole blood of the 50 studied Egyptian
patients, as regards mutation of exon 7 of the p53
gene using the PCR-RFLP technique, revealed that
in group II (liver cirrhosis) and the control group no
point mutation at codon 249 of exon 7 could be
detected, while in the HCC group 3/20 patients
(15%) showed the mutation at codon 249 of exon 7.
These results were in agreement with another 
study done in Egypt by Mona et al. [14], who
reported that in the control group, 20 subjects had
no point mutation at codon 249 of exon 7 while in
the HCC group out of 30 patients 4 patients (13.3%)
showed a point mutation at codon 249 of exon 7
(in both tissue and blood samples). They also
reported that out of 30 HCC patients 13 patients
(43.3%) showed loss of heterozygosity at codon 72
of exon 4 of the p53 gene. This finding was in both
tumourous tissue samples and the whole blood
samples of the same HCC patients. 
Tumour-specific mutations of the p53 gene often
lead to synthesis of a faulty protein that has lost
its normal growth regulatory functions. The
mutation of the p53 gene in HCC suggests that loss
of normal gene function may be a key step during
malignant transformation of hepatocytes. In our
study, most patients with the 249ser mutation have
a corresponding wild-type allele. One of 3 patients
was homozygous for the mutation (both alleles of
the p53 gene were mutated), while the other 
2 patients were heterozygous for the same mutation.
This was in agreement with Mariana et al. [15], who
suggested that loss of the wild-type allele may be
required for the mutant to exert its effect. This
observation may support the hypothesis that 249ser
mutations are recessive and do not have the
dominant negative function reported for some
other p53 mutations. 
As regards the relation between exon 7 mutation
and viral markers, our study showed that among
the 14 HCV-Ab seropositive HCC patients there were
3 (21.4%) showing mutation at codon 249 of exon 7
of the p53 gene in their blood sample. Our results
also demonstrated 2 patients with combined HCV
and HBV in group I HCC patients, 1 of whom
showed exon 7 mutation (50%). 
Several reports have documented that prior HBV
infection, characterized by presence of anti-HBc,
affects the development of HCC in patients infected
with HCV. Other authors, however, were not able to
document any adverse event of occult HBV
infection on the clinicopathological course of
chronic HCV infection [16]. On the other hand, our
study cannot clarify the fact, as it only included 
2 patients out of 30 who suffer from HCC and
showed HCV-Ab and HBcAb in their sera. Their
clinical data showed no difference compared to
other cases with HCC and lacking this coinfection.
Most HCCs are associated with chronic liver
diseases resulting from hepatitis B or C viral
infection, and the processes of chronic inflam  -
mation and fibrosis act as a stressful condition. Heat
shock proteins induced in response to this stress
condition may contribute to hepatocarcinogenesis.
Until now there have been a few comprehensive
studies of the expression of HSP70; however, its
prognostic relevance remains controversial. In
addition, there have been few studies on HSP
expression in association with tumour cell
proliferation or apoptosis in HCCs. However, no
prospective epidemiological data evaluating this
gene family are available.
Three of the HSP70 are mapped within the major
histocompatibility complex (MHC) class III region
on the short arm of chromosome 6. These are
intron-less HSP70-1, HSP70-2 and HSP70-Hom,
which have a homologous gene sequence but differ
in their regulation. There are 14 polymorphic sites
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within these 3 MHC-linked HSP70: 6 in HSP-1 and
4 each in HSP-2 and HSP-Hom. 
Our aim was to investigate whether poly  -
morphism in the gene for heat shock protein 70
(HSP70) has any bearing on individual susceptibility
to the development of hepatocellular carcinoma
(HCC). The genotypes of HSP70 genes 1 and 2 of
our patients were analysed using polymerase chain
reaction followed by restriction fragment length
polymorphism.
HSP70-1 b2-b2 genotype frequency was
dominant in the control group (100% b2-b2), as well
as in the HCC group (95% b2-b2; 20% b1-b1) and in
cirrhotics (80% b2-b2; 20% b1-b1). There was no
statistically significant difference between the 
3 groups regarding the frequency of the polymorphic
genotypes (p > 0.05). Our results suggested that
genetic polymorphism in HSP70-1 is not associated
with the risk of future development of HCC in
Egyptian patients.
HSP70-2 B/B genotype frequency was increased
in the whole group of patients. The A/A genotype
was the least frequent among the 3 groups. The 
B allele was increased among all the groups. In the
HCC group the genotype frequency was A/A 0%,
A/B 25% and B/B 75%. Among cirrhotics, it was
10%, 20% and 70%, respectively. In the control
group the genotype frequency was 0%, 50% and
50%, respectively. The frequency of polymorphic
genotypes showed no significant difference
between the 3 studied groups as regards HSP70-2
(p > 0.05).
Chuma et al. [17] compared expression profiles
among early components and progressed
components of nodule-in-nodule-type HCCs and
their corresponding non-cancerous liver tissues with
oligonucleotide array. Of these genes, the most
abundantly upregulated gene in early HCC
components was heat-shock protein 70 (HSP70).
Real-time quantitative reverse transcription
polymerase chain reaction (RT-PCR) confirmed this
finding. Further immunohistochemical examination
of HSP70 revealed its significant overexpression in
early HCC compared with precancerous lesions and
in progressed HCC compared with early HCC. Thus,
molecular signatures were clearly different in non-
cancerous liver tissue as compared with the early
and progressed components of nodule-in-nodule-
type HCC. Moreover, HSP70 could be a sensitive
marker for the differential diagnosis of early HCC
from precancerous lesion or non-cancerous liver,
a difficult distinction for pathologists due to very
well differentiated histology with little atypia in
early HCC. Expression of HSP70 may play an
important role in hepatocarcinogenesis, and in
particular HSP70 can contribute to tumour
progression by promoting tumour cell proliferation
in HCC [7].
In conclusion, the present study supports the
view that the incidence of point mutation of p53
codon 249 is low among Egyptians. The hetero  -
zygous mutation of p53 exon 7 found in these
patients only indicates that they have genetic
susceptibility to HCC. Our results also suggested
that genetic polymorphism in HSP70-1 and 
HSP70-2 was not associated with the risk of future
development of HCC in Egyptian patients.
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